Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5) by Pagel, Julia et al.
CLINICAL TRIALS AND OBSERVATIONS
Distinct mutations in STXBP2 are associated with variable clinical presentations in
patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5)
*Julia Pagel,1 *Karin Beutel,2,3 Kai Lehmberg,2 Florian Koch,1 Andrea Maul-Pavicic,4 Anna-Katharina Rohlfs,5
Abdullah Al-Jefri,6 Rita Beier,7 Lilian Bomme Ousager,8 Karoline Ehlert,3 Ute Gross-Wieltsch,9 Norbert Jorch,10
Bernhard Kremens,11 Arnulf Pekrun,12 Monika Sparber-Sauer,13 Ester Mejstrikova,14 Angela Wawer,15 Stephan Ehl,4
†Udo zur Stadt,1,16 and †Gritta Janka2
1Research Institute Children’s Cancer Center, Hamburg, Germany; 2Department of Pediatric Hematology and Oncology, University Medical Center Hamburg
Eppendorf, Hamburg, Germany; 3University Children’s Hospital Mu¨nster, Pediatric Hematology and Oncology, Albert-Schweitzer-Campus 1, Mu¨nster, Germany;
4Centre of Chronic Immunodeficiency, University of Freiburg, Freiburg, Germany; 5Department of Voice, Speech and Hearing Disorders, University Medical
Center Hamburg Eppendorf, Hamburg, Germany; 6Section of Pediatric Stem Cell Transplantation, Department of Pediatric Hematology-Oncology, King Faisal
Specialist Hospital and Research Center, Riyadh, Saudi Arabia; 7Department of Pediatric Hematology and Oncology, Medical School Hannover, Hannover,
Germany; 8Department of Clinical Genetics, Odense University Hospital, Odense, Denmark; 9Pediatric Hematology, Oncology and Immunology, Klinikum
Stuttgart/Olga Hospital, Stuttgart, Germany; 10Gilead Children’s Hospital, Bielefeld, Germany; 11Pediatric Hematology, Oncology, University of Essen, Essen,
Germany; 12Prof Hess Children’s Hospital, Bremen, Germany; 13Department of Pediatrics, University of Ulm, Ulm, Germany; 14Department of Pediatric
Hematology and Oncology, Teaching Hospital Motol and 2nd Medical School, Charles University, Prague, Czech Republic; 15Department of Pediatrics, Technical
University Munich, Munich, Germany; and 16University Medical Center Hamburg Eppendorf, Center for Diagnostic, Hamburg, Germany
Familial hemophagocytic lymphohistiocy-
tosis (FHL) is a genetically determined
hyperinflammatory syndrome caused by
uncontrolled immune response mediated
by T-lymphocytes, natural killer (NK) cells,
and macrophages. STXBP2 mutations
have recently been associated with FHL5.
To better characterize the genetic and
clinical spectrum of FHL5, we analyzed a
cohort of 185 patients with suspected
FHL for mutations in STXBP2. We de-
tected biallelic mutations in 37 patients
from 28 families of various ethnic origins.
Missense mutations and mutations affect-
ing 1 of the exon 15 splice sites were the
predominant changes detectable in this
cohort. Patients with exon 15 splice-site
mutations (n  13) developed clinical
manifestations significantly later than pa-
tients with other mutations (median age,
4.1 year vs 2 months) and showed less
severe impairment of degranulation and
cytotoxic function of NK cells and CTLs.
Patients with FHL5 showed several
atypical features, including sensorineu-
ral hearing deficit, abnormal bleeding,
and, most frequently, severe diarrhea
that was only present in early-onset dis-
ease. In conclusion, we report the largest
cohort of patients with FHL5 so far, de-
scribe an extended disease spectrum,




Familial hemophagocytic lymphohistiocytosis (FHL) is a geneti-
cally heterogeneous hyperinflammatory syndrome caused by an
uncontrolled and ineffective proliferation and activation of T lym-
phocytes, natural killer (NK) cells, and macrophages that infiltrate
multiple organs, including liver, spleen, lymph nodes, and CNS,
and produce massive amounts of cytokines.
This overwhelming hyperimmune status results in a clinical
picture characterized by persistent fever, hepatosplenomegaly,
pancytopenia, hemophagocytosis in various tissues, coagulation
abnormalities, and inflammatory CNS disease. In the absence of
specific symptoms or laboratory values, the Histiocyte Society has
developed diagnostic criteria to facilitate diagnosis.1 In 70%-80%
of patients with FHL onset of disease is during infancy2; untreated
it is typically rapidly fatal.3,4
Treatment, including immunosuppressive drugs and chemo-
therapy, can resolve signs and symptoms in most cases, but the only
curative therapy is HSCT.
Disease-causing mutations have been identified in the genes
encoding perforin (PRF1; FHL2), Munc13-4 (UNC13D; FHL3),
and syntaxin 11 (STX11; FHL4).5-7 Furthermore, immunodeficien-
cies such as Griscelli syndrome type 2 (RAB27A), Che´diak-Higashi
syndrome (CHS1; LYST), Hermansky-Pudlak syndrome type
2 (AP3B1), and X-linked lymphoproliferative syndrome 1 and
2 (SH2D1A, XIAP) have been found to be associated with
hemophagocytic lymphohistiocytosis (HLH).8-15 The genes mu-
tated in FHL2-4, Griscelli syndrome type 2, and Che´diak-Higashi
syndrome encode proteins that are involved in the cytotoxic
granule pathway of CTLs and NK cells.16,17 These defects are
thought to contribute to the ineffective elimination of (viral) triggers
and down-regulation of immune responses that result in a sustained
hyperinflammatory state.4,18,19 Two groups have described STXBP2
mutations as being causative for FHL5.20,21 STXBP2 is part of the
Sec/Munc proteins that are important for the assembly and disassembly
of the SNARE (soluble N-ethylmaleimide–sensitive factor attachment
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protein receptor) complex and the control of membrane fusion. The role
of STXBP2 in the cytotoxic granule pathway is currently not understood
in detail, but it is known from previous studies that the protein is also
involved in the regulation of intracellular granule trafficking in epithelial
cells, neutrophils, and mast cells.22-24 RNA expression was also ob-
served in different hematopoietic cells, including T cells and mono-
cytes.20 Immunoprecipitation and Western blot experiments found a
direct interaction between Munc18-2 and syntaxin 11 that is absent in
patients with missense mutations in STXBP-2. These data strongly
suggest that both proteins are involved in the same granule exocytosis
pathway in vivo.20,21
So far, another 4 reports described mutations in STXBP2 in
small numbers of patients only.25-28
We present detailed genetic and clinical analyses of a large
cohort of 37 patients with FHL with biallelic STXBP2 mutations
from diverse ethnic origins and describe an extended clinical




Patients with suspected FHL (n 185) were included in this study. Patients
with biallelic mutations in PRF, UNC13D, and STX11 were excluded from
analysis. The patients had either been registered at the national HLH
reference center in Hamburg, Germany, or material for genetic studies had
been sent from various other countries, mainly Turkey. In patients with
confirmed biallelic STXBP2 mutations clinical data, including age at onset,
presenting features, treatment, and outcome, were extracted from documen-
tation forms and medical letters. Missing data were collected by contacting
the treating physicians. CNS involvement was assumed in the presence of
increased cerebrospinal fluid white blood count and/or protein, neurologic
symptoms, or abnormalities in magnetic resonance imaging, consistent with
HLH. All families gave their written informed consent to the genetic
analysis, immunologic studies, and clinical and laboratory data collection.
The study was conducted according to the guidelines of the Declaration of
Helsinki and has been approved by the local institutional review board.
Thirteen patients have been published in our original study,20 3 of which
plus 3 additional patients appear in the study of Rohr et al (patients P1-6).27
Five patients have been described clinically before the detection of the
genetic defect.29-31
Genetic analysis
Genomic DNA was isolated from peripheral blood by standard methods.
PCR was performed with specific primers for exon 1-19 of STXBP2,
including the adjacent intronic sequences for identification of splice-site
variants. The primers and general PCR conditions have been published
elsewhere.20 The PCR products were directly sequenced bidirectional with
the use of BigDye Terminator Version 1.1 (Applied Biosystems), and the
reactions were genetically analyzed on an ABI PRISM 3100. We confirmed
the mutations in the parents or by repeated experiments. For missense
mutations, healthy German/Turkish blood donors were used as controls to
exclude a polymorphism.
Immunoprecipitation
Immunoprecipitation experiments for the characterization of Munc18-2
missense mutations were performed as described previously.20 All missense
mutations and 2 different products of the exon 15 splice-site mutation were
Table 1. Overview of patients in group 1 without exon 15 splice-site mutations
Patient Consanguinity Ethnic origin
Age at







A_376  Swiss 2 mo c.87 2T C* 2 Splice site*
c.1621G A 18 p.Gly541Ser
A_724  Turkish 2 mo c.279delG* 5 p.Thr94ProfsX25* Abn (2.7%)/abn ND Abn
A_032  German 1 mo c.310A T* 5 p.Ile104Phe
c.1621G A 18 p.Gly541Ser
A_784a†  Turkish 2 mo c.502_dupC* 7 p.Gln168ProFsX71* Abn (0.82%)/eq ND Normal
A_784b†  Turkish 11 mo c.502_dupC* 7 p.Gln168ProFsX71* Abn (0.7%)/abn ND Abn
A_784c†  Turkish 1 mo c.502_dupC* 7 p.Gln168ProFsX71*
1155‡  Turkish 2 mo c.693_695delGAT 9 p.Ile232del
1945‡  Turkish 2 mo c.693_695delGAT 9 p.Ile232del
0884‡  Turkish 2 mo c.875G A 10 p.Arg292His
1948-1†‡  Turkish 3 mo c.1214G A 14 p.Arg405Glu
1948-2†  Turkish 2 mo c.1214G A 14 p.Arg405Glu
1949‡  Turkish 9 mo c.1213C T 14 p.Arg405Trp
1976-1†‡  United Arab Emirates 6 mo c.1430C T 16 p.Pro477Leu Eq (5.3%)/nd ND ND
1976-2†  United Arab Emirates 2 mo c.1430C T 16 p.Pro477Leu Abn (4.5%)/nd Reduced Abn
1875†‡  Saudi Arab 4 mo c.1430C T 16 p.Pro477Leu
1875b†  Saudi Arab 1 mo c.1430C T 16 p.Pro477Leu
A_679  United Arab Emirates 1 mo c.1430C T 16 p.Pro477Leu Abn (0.5%)/eq Abn ND
A_244a†§ Austrian 2 mo c.1696 1G A* 18 Splice site*
A_244b†§ Austrian 5 d c.1696 1G A* 18 Splice site*
A_474  Danish 2 mo c.1601C T* 18 p.Leu534Pro*
c.1621G A 18 p.Gly541Ser
A_142a†  Sri Lanka 3 d c.1697G A* 19 p.Gly566Asp*
A_142b†  Sri Lanka 2 mo Not tested
A_751a†  Lebanese 2 mo c.1727delT* 19 p.Phe576SerfsX4* Abn (0.89%)/abn ND normal
A_751b†  Lebanese 1 mo c.1727delT* 19 p.Phe576SerfsX4* Abn (0.17%)/nd ND ND
Abn indicates abnormal; ND, not done; and eq, equivocal.
*Novel mutations.
†Siblings or cousins.
‡Patients already published by zur Stadt et al.20
§Patients already published by Matthes-Martin et al in 200029 and by Kapelari et al.30
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cloned into the eukaryotic expression vector pEGFP-C2 (BD Bioscience): a
cDNA that harbors the c.1247-1356 deletion of the complete 110 nucleo-
tides of exon 15, resulting in a premature stop of the protein sequence and
an artificial in-frame deletion of exon 15 that deletes nucleotide c.1246-
1356 (p.416_452) of the Munc18-2 protein.
Degranulation and cytotoxicity assays
NK-cell and CTL degranulation and cytotoxicity assays were performed
according to the protocols described previously.32 Normal values were
established in that study by prospective evaluation of these assays in
90 healthy donors and a large cohort of patients with primary and secondary
HLH. On the basis of these data, for the present study resting NK-cell
degranulation  5% was considered to be abnormal, and values  10%
were considered to be normal. For IL-2–stimulated NK cells, values 20%
were considered as abnormal and values  30% as normal. Any values in
between were classified to be reduced. CTL degranulation 15% was
classified as normal,  10% as abnormal, and between 10% and15% as
reduced. Values for NK-cell and CTL cytotoxicity were read from titration
curves at an NK/target ratio of 3:1 or a CD8 T cell/target ratio of 10:1,
respectively. For both tests, values  40% lysis (ie, the 10th percentile of
90 healthy donors) were considered to be reduced; values  10% were
considered to be abnormal. In an additional 6 patients, NK-cell activity was
performed in another laboratory. Because variable NK cell/target ratios
were used, decreased NK-cell cytotoxicity in these patients could not be
clearly categorized according to the definitions above and was therefore
classified as impaired.
Statistics
Statistical analysis was performed with PASW statistics 18 (SPSS Inc).
Significance of differences between patient groups was calculated with the
2 test for nominal variables and Welch test for metric variables. Differ-
ences were considered significant at a P value  .05.
Results
Genetic features
We identified biallelic mutations in STXBP2 in 37 patients from
28 unrelated families. In addition to the 16 patients who were
recently published, we found homozygous or compound heterozy-
gous mutations in another 21 patients from 15 independent
families. In one patient no sample for genetic testing was available.
He was included despite missing genetic analysis because he had a
clear-cut clinical HLH picture, and a biallelic STXBP2 mutation
had been identified in the brother (Tables 1 and 2).
Nine novel mutations were detected (Figure 1). The spectrum of
STXBP2 mutations in the entire cohort comprises small deletions or
insertions, 9 different missense mutations, and 4 different splice-
site mutations. Mutations are scattered over the entire coding
region with some mutations being relatively frequent: c.1430C T
(p.Pro477Leu), detected in 5 patients of Arab origin, and c.1621G
 A (p.Gly541Ser), found in 7 patients of mainly white origin. The
mutation c.1247-1 G  C that affected the splice acceptor site of
exon 15 was identified in 12 patients, 5 times homozygous and
7 times in combination with another mutation. One further patient
had a compound heterozygous mutation pattern that affected the
splice donor site of exon 15 on one allele (c.1356 1G  A)
together with the c.1621G A (p.Gly541Ser) missense mutation
in exon 18. These splice-site mutations occurred predominantly in
German and Turkish patients.
Interaction studies between Munc18-2 and syntaxin 11
To better characterize the nature of the missense mutations and
in-frame deletions we performed an immunoprecipitation assay













2290* German 1.3 c.260delT 5 p.Leu87ArgfsX32
c.1247-1G C 15 splice site
0870*† German 2.3 c.626T C 8 p.Leu209Pro Eq (5.05%)/ Abn Normal
c.1247-1G C 15 splice site normal
2291* Czech 1.3 c.706delG 9 p.Ala236GlnfsX24
c.1247-1G C 15 splice site
0879*†‡§  Turkish 2.4 c.1247-1G C 15 splice site Eq (6.8%)/ND Normal Normal
0879a‡§  Turkish 1.3 c.1247-1G C 15 splice site
A_603  Turkish 1.6 c.1247-1G C 15 splice site
A_721†  Turkish 9 c.1247-1G C 15 splice site Abn (4.1%)/normal ND Normal
2289*† German 3 c.1247-1G C 15 splice site Abn (0.06%)/abn Abn Normal
A_213  German 14 c.1247-1G C 15 splice site
c.1621G A 18 p.Gly541Ser
A_726†  German 7 c.1247-1G C 15 splice site Abn (2.4%)/ ND Normal
c.1621G A 18 p.Gly541Ser Normal
A_770  German 19 c.1247-1G C 15 splice site Abn (3.28%)/ Abn Normal
c.1621G A 18 p.Gly541Ser Normal
A_771  German/Indonesian 6 c.1247-1G C 15 splice site Abn (0.3%)/ Abn Normal
c.1724_1729delGCTTCC¶ 19 p.Arg575_Phe576del¶ Abnormal
A_711†‡  German 13 c.1356 1G A 15 splice site Abn (0.5%)/ ND Normal
c.1621G A 18 p.Gly541Ser Eq
Eq indicates equivocal; abn, abnormal; and ND, not done.
*Patients already published by zur Stadt et al.20
†Patients already published by Rohr et al.27
‡Patients already published by Beutel et al.31
§Siblings or cousins.
¶Novel mutations.
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that allows testing of the interaction capacity of mutated Munc18-2
with wild-type syntaxin 11. A weak-to-absent binding to syntaxin
11, comparable with the results observed for Munc18-2 missense
mutations, was found for the 2 exogenous constructs of exon
15 splice-site mutations (Figure 2).
Cytotoxicity and degranulation assays
Data on NK cytotoxicity were available from 12 patients and
showed pathologic results (“impaired,” “abnormal,” and “re-
duced”) in 11 of them (supplemental Table 1, available on the
Blood Web site; see the Supplemental Materials link at the top of
the online article). Detailed functional testing of cytotoxic and
degranulation capacity of NK and/or T cells with standardized
methods was performed in 16 patients from 14 unrelated families in
one reference laboratory (Tables 1-2). NK degranulation was
analyzed in all 16 patients and showed a clear deficiency in 13 and
reduced degranulation in 3. NK degranulation after IL-2 stimula-
tion was tested in 12 patients and was abnormal in 5 and reduced
in 3 patients, all of whom also had abnormal resting NK-cell
degranulation. Interestingly, 4 patients with abnormal resting
NK-cell degranulation showed normal degranulation of IL-2–
activated NK cells. Degranulation of CTLs was tested in 14 pa-
tients and was abnormal in 10 and reduced in 4 patients. CTL
cytotoxicity was normal in 10 of 13 patients and reduced in the
remaining 3 patients.
Clinical characteristics of patients with FHL5
Detailed clinical data of the 37 patients with FHL5 from
28 unrelated families are shown in the supplemental Table 1, a
summary of which is presented in Table 3. Fourteen patients
originated from Central Europe, 14 from Turkey, 7 from the
Middle East, and 2 from Sri Lanka. Consanguinity of the parents
was reported in 19 of 35 patients. Twenty-three of 36 patients
had a positive family history of HLH. The age at diagnosis
ranged from 3 days to 19 years with a median age of 3 months.
At diagnosis, most patients fulfilled the HLH-2004 diagnostic
criteria; in 5 patients the data on HLH criteria were incomplete.
Most patients showed signs of liver involvement such as
hepatomegaly, elevation of liver enzymes, hyperbilirubinemia,
and/or low protein/albumin. CNS involvement was observed in
55% of the patients. Treatment according to the HLH-1994/2004
study protocols was administered in 26 patients; another 2 were
treated with a modified protocol (supplemental Table 1). Five
patients received different combinations of corticosteroids,
immunoglobulins, antibiotics, or plasmapheresis. In one patient,
Hodgkin disease stage III B was diagnosed at the age of 9 years.
Retrospective evaluation found the presence of typical HLH
features at that time. Both Hodgkin disease and HLH symptoms
responded to the treatment according the German Hodgkin
lymphoma protocol. At the age of 10 years, still in remission of
Hodgkin disease, an HLH relapse occurred.
The course of disease showed a considerable variability in this
cohort. Part of the patients displayed an early onset and a severe
and rapid progression of disease; others had a late onset and a
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Figure 1. Spectrum of Munc18-2 mutations detected in our cohort. New mutations are shaded in gray. Three mutations were seen in 5 patients: 13 patients had mutations affecting
one of the exon 15 splice sites, 7 patients from central Europe had p.Gly541Ser, and 5 patients ofArab origin had p.Pro477Leu. For details see Tables 1 and 2.
Figure 2. Coimmunoprecipitation analysis for binding between Munc18-2 and
syntaxin 11 proteins. All immunoprecipitation reactions were performed with
exogenous constructs with the use of either an Ab specific for Flag (syntaxin 11) or for
enhanced green fluorescent protein (EGFP; Munc18-2). No endogenous proteins
were analyzed. Exposition time of the x-ray film was 15 seconds. Lanes 1 through
3 show control samples, lane 4 shows the Munc18-2 construct as identified as the
main RNA product detected in 2 of our patient samples with a homozygous exon
15 splice-site mutation. Lane 5 shows an artificial construct that contains an in-frame
deleted exon 15. Lanes 6 and 7 are constructs representing missense mutations with
nearly absent syntaxin binding. All Munc18-2 constructs, representing the different
kind of mutations, show comparable loss of binding for syntaxin.
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chronic recurrent course with sometimes long episodes of well-
being and absence of HLH symptoms without therapy. In 8 patients
with a partial or full HLH reactivation, response to steroids or
unspecific treatment only could be observed.
HSCT was performed in 26 patients (19 from matched related
or unrelated donors) at a median age of 1 year (range, 4 months to
24 years). Conditioning regimens consisted of busulfan, cyclo-
phosphamide with or without etoposide in half of the patients;
10 received fludarabine-based regimens. Most patients had nonac-
tive disease before HSCT. Median follow-up after HSCT is 4 years
(range, 5 months to 16 years). Six patients died of transplantation-
related complications. Surviving patients have remained free of
HLH symptoms except 2 who are alive with mild HLH reactiva-
tions after rejection of the graft. Eight patients died of HLH or HLH
therapy–related complications without HSCT within the first year
of disease onset. Causes of death are listed in supplemental Table 1.
Two patients are alive without HSCT, 13 and 2 years, respectively,
after onset of disease but are currently evaluated for HSCT because
of recent reactivations.
Unusual clinical features
Gastrointestinal symptoms. In 14 patients, severe chronic diar-
rhea was described which resulted in failure to thrive even in the
first months of life. All patients except one who received feeding by
percutaneous endoscopic gastrostomy tube needed long-term paren-
teral nutrition. Weight was below the third percentile in most of the
patients. Height was below the third percentile in all patients who
survived long enough for evaluation. Diarrhea was often present
before the diagnosis of HLH. Extensive clinical investigations,
including biopsies in 6 patients (5 after HSCT), failed to detect a
specific cause of their gastrointestinal symptoms. Histology was
normal in the patient without HSCT and showed unspecific
changes such as discrete inflammation and slight loss of villi or
crypts in the other patients. The diarrhea did not respond to HLH or
unspecific treatment, even if HLH symptoms had been controlled.
In 6 of 8 patients who had undergone HSCT, severe diarrhea
persisted even after transplantation. In 1 patient, the information is
missing, in the other patients it is not available yet, because HSCT
has been performed recently.
Hearing deficit. Sensorineural hearing loss was documented
in 6 patients between 4-17 years of age. Pure tone audiometry
found a mild-to-moderate low-frequency hearing impairment. Two
children experienced additional conductive hearing loss (maximum
25 and 60 dB, respectively).
Hypogammaglobulinemia. Hypogammaglobulinemia is an-
other unusual clinical symptom that has been observed in 10 of
17 patients. Three of them have already been included in the report
on atypical patients by Rohr et al.27 Most patients had a chronic
course that repeatedly required intravenous immunoglobulin
infusions.
Bleeding tendency. Bleeding problems were reported in
8 patients. In 4 patients major bleeding occurred in the presence of
disease- or transplant-related abnormalities of coagulation or
platelets. In 2 siblings unexplained recurrent bleeding symptoms
have been observed. In one further patient pulmonary hemorrhage
during the early period after transplantation was judged as atypical
and not clearly associated with HSCT by the treating physicians. In
4 patients a specific platelet secretion defect has been found (for
details see Sandrock et al33). Only 1 of them displayed bleeding
symptoms.
Genotype-phenotype correlation
Patients were classified into 2 distinct subgroups: group 1 carrying
biallelic missense mutations, in-frame, or frameshift deletions and
splice-site mutations other than exon 15 and group 2 with either
homozygous or compound heterozygous mutations with 1 allele
carrying an exon 15 splice-site mutation (Table 4).
The 24 patients of group 1 had a heterogeneous ethnic
background. All of them had a classic course of disease with an
early onset before 1 year of age (median, 2 months) and a rapidly
fatal course if HSCT could not be performed. This group also
comprises all 14 cases with diarrhea. Only one of these patients
was diagnosed to have hypogammaglobulinemia. In contrast, the
13 patients of group 2, mainly from central Europe, with exon
15 splice-site mutations on 1 allele showed a relatively mild and
atypical course of FHL. They were diagnosed at a median age of
3 years (range, 1.3-19 years). Most of them developed a chronic
recurrent course with long episodes of absent HLH symptoms and
recurrent reactivations with spontaneous remissions or response to
therapy with steroids only. None of these patients had diarrhea;
however, in 9 patients hypogammaglobulinemia was observed.
HSCT was performed in 10 patients at a median age of 9 years
(range, 2.4-24 years). Two further patients, 11 and 15 years old, are
awaiting HSCT. Age at diagnosis, frequency of hypogammaglobu-
linemia, and frequency of episodes with spontaneous remission or
response to steroids only were significantly different in group
2 than in group 1.
In 8 patients with missense mutations who were tested at the
reference laboratory, NK-cell degranulation was abnormal in 7 and
showed reduced responses between 5% and 10% in 1 patient. CTL
degranulation was abnormal in all tested patients. No patient
regained normal NK degranulation on IL-2 stimulation. CTL
cytotoxicity was analyzed in 5 patients of this cohort and was
abnormal in 3 and normal in 2 of them.
In 8 patients with exon 15 splice-site mutations NK-cell
degranulation was abnormal in 6 and reduced in 2 patients. CTL
degranulation was abnormal in 4 patients and reduced in the other
Table 3. Summary of clinical data of 37 patients with FHL5
Value




Middle East, n 7
Far East Asian, n 2
Male:female 17:20
Median age at diagnosis (range) 3 mo (3 d to 19 y)
 5 HLH criteria fulfilled† 32/37
Abnormal NK degranulation 13/16
CNS involvement 15/27
Treatment with HLH 94/2004 26/34
HSCT 26/36
Median age at HSCT (range) 1 y (4 m to 24 y)
Outcome alive 22/36
Alive without HSCT 2‡
Death from HLH 8
Alive after HSCT 20
Death from TRM 6
TRM indicates transplant-related mortality.
*In 1 of these patients, the father was white and the mother was Far East Asian.
†In the 5 patients who did not fulfill  5 criteria, reporting on criteria was
incomplete.
‡Both patients are currently listed for HSCT.
6020 PAGEL et al BLOOD, 21 JUNE 2012  VOLUME 119, NUMBER 25
For personal use only.on January 29, 2017. by guest  www.bloodjournal.orgFrom 
4 patients. In contrast to patients with missense mutations, on IL-2
stimulation NK-cell degranulation returned to normal in 4 of
7 patients. CTL cytotoxicity was normal in all 8 patients.
Discussion
This is the largest cohort of patients with FHL5 reported so far with
37 patients from a widespread ethnic origin. In contrast to FHL4,
which seems to be more frequent in the Turkish and Arab
population, FHL5 does not appear to be restricted to a specific
geographic region. STXBP2 mutations were found in a consider-
able number of patients from Central Europe, thus contributing to
the characterization of genetic defects in a population with many
previously genetically undefined patients with FHL.
STXBP2 mutations are scattered all over the gene and comprise
homozygous and compound heterozygous mutations in 25 and
12 patients, respectively. Nine novel mutations were found. We
identified a large group of 13 patients with a splice-site mutation
affecting exon 15 (either c.1247-1G C or c.1356  1G  A;
group 2). Together with the other published FHL5 cases, the
c.1247-1G C splice-site mutation is the most common mutation
detected so far.21,25-28
The predicted effect of this splice-site mutation at the protein
level remains unclear. In our cDNA analysis from 2 homozygous
patients, we predominantly detected a transcript that results in a
truncated protein (c.1247-1G C; p.Val417LeufsX126) contain-
ing a large stretch of 126 out-of-frame amino acids without any
residual functional domains. In addition, several other out-of-frame
and in-frame constructs were observed; however, they were
observed as minor fractions visible only after cloning of the
corresponding cDNA fragment.20 Cote et al described for the same
splice-site mutation an in-frame product that resulted from an
exchange of the first 17 aa of exon 15 by 19 aa from the intron 14.21
Western blot analysis of lymphoblasts showed residual
Munc18-2 protein for patients with a homozygous exon 15 splice
acceptor site mutation, yet of reduced intensity and probably with a
slightly reduced molecular weight. Both research groups also
showed a reduced but not absent expression of syntaxin 11, a
proven interaction partner of Munc18-2 which itself is mutated in
patients with FHL4.20,21 To explain at least in part the nature of this
splice-site mutation we tested the in vitro syntaxin 11 binding
capacity of our main out-of-frame construct (c.1247-1G C;
p.Val417LeufsX126) and of an artificial construct that completely
deletes exon 15 in frame. As in missense mutations none of them
showed a clear binding, indicating that other effects cause the
phenotypic variation between patients with exon 15 splice-site mutation
compared with patients with a missense or nonsense mutation.
Deficient NK-cell degranulation seems to be a uniform finding
in all patients with FHL5, and IL-2–mediated reconstitution in
some of them has also been described by other groups.21,26
However, in line with a prior observation of our group,27 we could
establish a clear association of reconstitution of NK-cell degranula-
tion with distinct mutations. Defective NK-cell degranulation
improved after IL-2 stimulation in most patients with exon
15 splice-site mutations (group 2) but not in patients with other
mutations (group 1). CTL cytotoxicity was normal in all patients
from group 2, whereas it was abnormal in 3 patients from group 1.
The results of the immunologic studies in our patients therefore
support the assumption of a residual function of exon 15 splice-site
mutations compared with a deleterious effect of the other mutations.
Although it remains to be clarified how these in vitro processes
can be translated into in vivo pathomechanisms, there seems to be
an association with the clinical picture. The median age at
diagnosis in our whole cohort was 3 months with a range from
3 days to 19 years.
Patients with either homozygous or compound heterozygous
exon 15 splice-site mutations had a late onset of disease  1 year
Table 4. Genophenotype correlation
Group 1, without exon 15
splice-site mutations
Group 2, with exon 15 splice-site
mutations on> 1 allele P
Patients, n 24 13
Sex, male/female, n 11/13 6/6 .99
Ethnic origin .02
White, n 5 9
Turkish, n 10 4
Arab, n 7 0
Asian, n 2 0
HLH in family, n/N 20/24 3/12
Consanguinity, n/N 17/22 3/13
Median age at diagnosis (range) 2 mo (3 d to 11 mo) 3 y (1.3-19 y) .003
Episodes with partial or full HLH and
remission spontaneously or to
steroids only, n/N
1/21 7/12 .0004
Chronic diarrhea, n/N 14/19 0/11 .0001
Hypogammaglobulinemia, n/N 1/8 9/10 .001
Platelet secretion defect, n/N 2/2 2/2
HSCT, n/N 16/24 10/12
Median age at HSCT (range) 6 mo (4 mo to 1.6 y) 9 y (2.4-24 y)
Median age at death (range) 7 mo (9 d to 1.3 y) 8 y (6-16 y)
Outcome alive, n 14 8
Alive without HSCT, n 0 2
Death from HLH, n 8 0
Alive after HSCT, n 14 6
Death from TRM, n 2 4
TRM indicates transplant-related mortality.
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of age and frequently courses with long episodes of nonactive
disease or mild reactivations. In contrast, patients in group
1 carrying mutations other than at exon 15 splice sites (mainly
missense mutations) had a typical course of FHL with a signifi-
cantly earlier diagnosis  1 year of age and a severe course that
required early HSCT or resulted in fulminant death. This phenotype/
genotype correlation has already been suggested previously in a
smaller number of patients.21
Compared with other FHL types, median age of diagnosis in the
whole FHL5 cohort seems to be similar to that found in patients
with FHL2 (3 months) and is slightly less than in patients with
FHL3 (4 months). In patients with FHL4 the age of onset varies
widely with a median of 14 months. Interestingly, patients with
FHL2 and patients with FHL3 with missense mutations have a
significantly later onset of disease than patients with nonsense
mutations.34-36
As has been described for patients with FHL5 before, our
patients also displayed a large spectrum of features that are not
part of the typical HLH clinical picture.26,27 Previous studies
have reported an ubiquitous Munc18-2 RNA expression not
restricted to hematopoietic cells, suggesting a role of the protein
in vesicle transport in many mammalian tissues.37 In mouse
embryonic tissues Munc18-2 protein expression has been found
in the apical surface of epithelial cells of the intestine, kidney,
lungs, spleen, and testes.38 Unless there are alternative pathways
in these cell types, as it is for the case for rab27a in platelets,
Munc18-2 deficiencies would therefore be expected to cause
diverse clinical manifestations.
The most frequent symptom in 14 patients of our cohort was
severe diarrhea that often affected the patients before they devel-
oped classic HLH symptoms. Most of these patients needed
parenteral feeding. Diarrhea persisted during HLH treatment and
even after HSCT, often resulting in failure to thrive and always in
growth retardation. Because other causes of chronic bowel disease
have been ruled out in our patients, we assume that diarrhea is a
feature of the underlying genetic defect. In addition, we show a
clear association with patients in group 1, indicating that patients in
group 2 might have a residual function of the protein.
The pathophysiology of the diarrhea is not yet understood.
Colocalization of Munc18-2 with syntaxin 3 was shown to be
involved in the regulation of apical membrane transport in murine
intestinal cells and in a colon carcinoma cell line.39 Defective
Munc18-2 expression in epithelial cells of the human gut may
therefore lead to disturbed regulation of secretory pathways.
There is evidence of a role of STXBP2 in platelet function. Four
of our patients were tested for functional defects, and a distinct
secretion defect could be found.33 The abnormality was not
restricted to a group of patients with specific mutations or course of
disease. Only one of them developed a major hemorrhage, question-
ing the clinical significance of this finding.
However, Meeths et al have also described an increased
bleeding tendency in some of their patients with FHL5.26 Episodes
of abnormal bleeding have been observed in 7 patients of our study.
In a setting associated with different coagulation disorders and a lot
of comorbidities that also can result in hemorrhage, it is difficult to
identify the main underlying cause. We therefore recommend
platelet function testing in all patients with FHL to better define the
association with specific genetic defects. Closer observation of
affected patients might then contribute to a more profound
understanding of the clinical consequences.
Hearing impairment is a feature that so far has not been reported
in patients with FHL5. The only report on sensorineural hearing
loss in FHL describes a patient with a perforin defect who had
hearing loss that affected all frequencies.40 We have observed
low-frequency hearing impairment in 6 of 17 patients with FHL for
whom clinical information or test results were available.
Sensorineural hearing impairment affecting low frequencies is a
rare event in early childhood. Typical causes of hearing loss in
critically ill patients are toxic effects of drugs which result in
high-frequency hearing impairment.
Low-frequency hearing is located at the cochlear apex.
Known causes for low-frequency hearing loss include rare
hereditary disorders,41 Menie`re’s disease, autoimmune pro-
cesses, viral infection, allergy, or ischemia. Low-frequency
hearing impairment can easily remain undetected because it
does not affect listening to the frequencies of normal speech. It
might therefore become obvious only in later life, that is, in
long-term survivors of HLH. Specific testing would be neces-
sary to determine the low-frequency hearing threshold42 and to
better characterize the specific defect within the inner ear.43 It
therefore remains speculative if the underlying pathomechanism
in patients with FHL5 is associated with defective signal
transduction mechanisms in the inner ear or rather is the result
of an immunologic or inflammatory process. Future detailed
studies in patients with FHL5 and those with other genetic
background are recommended to understand this phenomenon
and its possible relation with specific genetic defects.
Overlapping symptoms with chronic variable immunodefi-
ciency such as hypogammaglobulinemia have already been de-
scribed in patients with FHL5.26,27 Ten patients of our cohort were
reported to have persistent hypogammaglobulinemia. Most of them
belonged to group 2, harboring an exon 15 splice-site mutation as
did the patients reported by Meeths et al.26 The finding that patients
with FHL3 also may be affected and that hypogammaglobulinemia
was not preexistent but developed during the course of the disease
argues against a specific causative role of STXBP2 mutations. The
demonstration of an impaired B-cell maturation in some patients
favors a role of a defective B- to T-cell interaction for the
development of hypogammaglobulinemia in the persistent hyperin-
flammatory condition of HLH. It might therefore become only
evident in patients with a long-term course of the disease as is the
case in patients with FHL5 with splice-site mutations.
Acquired HLH in association with malignant diseases, espe-
cially lymphomas, is a well-known entity. Our cohort includes one
patient with Hodgkin disease associated with incomplete HLH
symptoms at diagnosis. Genetic HLH was suspected when the HLH
symptoms reactivated. Subsequently, a homozygous exon 15 splice-site
mutation was identified. So far, it is not known whether carriers of
STXBP2 mutations have a higher risk of developing malignant diseases,
as has been suggested for patients with PRF1 or STX11 mutations.44,45
In conclusion, we present the so far largest cohort of patients
with FHL5 of various ethnic origins with a wide spectrum of
mutations and report a clear genophenotype correlation. Patients
with FHL5 who carry missense mutations have a higher risk of
early onset, severe disease and development of chronic diarrhea. In
contrast, patients with exon 15 splice-site mutations are character-
ized by a later onset and, if HSCT is not performed, frequent mild
reactivations that, however, may eventually result in permanent
consequences and death. FHL5 should be considered as a differen-
tial diagnosis in patients with incomplete HLH symptoms in the
presence of additional symptoms, including abnormal bleeding,
hearing deficit, or overlapping features with other immunodeficien-
cies such as hypogammaglobulinemia. In such atypical cases
functional analyses that can guide subsequent genotyping are
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recommended as well. A murine model of STXBP2 deficiency is
needed for identifying the underlying pathomechanisms.
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